Tim Boreham, Stockhead's small caps correspondent joins The Australian's Wealth Editor James Kirby on this week's show. They discuss how Biotech gets hit hardest of all, one reason this sector may recover first and three ASX biotech stocks for you to consider.

Healthy rebound: How the ASX got its mojo back
41:44

Property pile-up warning: Bracing for a listings overhang
28:17

The hunt for income heats up
40:06